AstraZeneca’s Acquisition of Brazikumab

Debevoise & Plimpton LLP and Ropes & Gray advised Allergan plc on the deal.

AstraZeneca entered into an agreement to acquire brazikumab (IL-23 inhibitor) from Allergan. AstraZeneca (LSE/STO/NYSE: AZN) will acquire brazikumab, an investigational IL-23 inhibitor in Phase 2b/3 development for Crohn’s Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world

Brazikumab is a monoclonal antibody that binds to the IL23 receptor and is in development for Crohn’s Disease and Ulcerative Colitis with a companion biomarker. Brazikumab selectively blocks the IL23 immune signal, preventing intestinal inflammation. The Phase IIb/III INTREPID program is underway to assess brazikumab compared to placebo or adalimumab in Crohn’s Disease. The Phase II EXPEDITION trial is underway to assess brazikumab compared to placebo or vedolizumab in Ulcerative Colitis.

The Debevoise team is led by M&A partner Andrew Bab (Picture) and includes M&A partners Jennifer Chu, Sue Meng and Thomas Schürrle, counsel Molly Stockley and associates William Barlow, Lauren Beasley, David Becker, Zhiyan Cao, Benjamin Collins-Wood, Michelle Guo, James Harrington, Gabriel Pollack and Friedrich Popp, tax partner Gary Friedman and associate Samuel Krawiecz, benefits partner Jonathan Lewis, intellectual property partner Henry Lebowitz and associate Jose Lamarque and FDA regulatory partner Paul Rubin and associate Melissa Runsten.

The Ropes & Gray team was led by strategic transactions partner Marc Rubenstein and associate Julienne Hearn and included litigation & enforcement partners Mark Popofsky(Washington, D.C.) and Richard Batchelder (Boston).

Involved fees earner: Andrew Bab – Debevoise & Plimpton; William Barlow – Debevoise & Plimpton; Lauren Beasley – Debevoise & Plimpton; David Becker – Debevoise & Plimpton; Zhiyan Cao – Debevoise & Plimpton; Jennifer Chu – Debevoise & Plimpton; Benjamin Collins-Wood – Debevoise & Plimpton; Gary Friedman – Debevoise & Plimpton; Michelle Guo – Debevoise & Plimpton; James Harrington – Debevoise & Plimpton; Samuel Krawiecz – Debevoise & Plimpton; Jose Angel Lamarque III – Debevoise & Plimpton; Henry Lebowitz – Debevoise & Plimpton; Jonathan Lewis – Debevoise & Plimpton; Sue Meng – Debevoise & Plimpton; Gabriel Pollack – Debevoise & Plimpton; Friedrich Popp – Debevoise & Plimpton; Paul Rubin – Debevoise & Plimpton; Melissa Runsten – Debevoise & Plimpton; Thomas Schürrle – Debevoise & Plimpton; Molly Stockley – Debevoise & Plimpton; Richard Batchelder – Ropes & Gray; Julienne Hearn – Ropes & Gray; Mark Popofsky – Ropes & Gray; Marc Rubenstein – Ropes & Gray;

Law Firms: Debevoise & Plimpton; Ropes & Gray;

Clients: Allergan;

Print Friendly, PDF & Email

Author: Ambrogio Visconti